VLP Production from Recombinant L1/L2 HPV-16 Protein Expressed in Pichia Pastoris

Sanchooli, Alireza; Aghaiypour, Khosrow; Kiasari, Bahman Abedi; Samarbafzadeh, Alireza; Ghadiri, Ataollah; Makvandi, Manoocher

doi:10.2174/0929866525666180809124633

Cited by 9 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The production system based on yeast allows for a low-cost product that is not restricted to small-scale basic research. In another study, Alireza et al (2018) produced chimeric protein L1/L2 VLPs in the P. Pastoris system by first inserting a cross-neutralizing epitope from the gene HPV-16 L2 into the gene L1 HPV-16. Following that, the chimeric L1/L2 HPV-16 had been introduced into the plasmid (pPICZA) and expressed in P. pastoris .…”

Section: Expression Host Systems For Virus-like Particle Productionmentioning

confidence: 99%

Virus-Like Particles: Revolutionary Platforms for Developing Vaccines Against Emerging Infectious Diseases

et al. 2022

View full text Add to dashboard Cite

Virus-like particles (VLPs) are nanostructures that possess diverse applications in therapeutics, immunization, and diagnostics. With the recent advancements in biomedical engineering technologies, commercially available VLP-based vaccines are being extensively used to combat infectious diseases, whereas many more are in different stages of development in clinical studies. Because of their desired characteristics in terms of efficacy, safety, and diversity, VLP-based approaches might become more recurrent in the years to come. However, some production and fabrication challenges must be addressed before VLP-based approaches can be widely used in therapeutics. This review offers insight into the recent VLP-based vaccines development, with an emphasis on their characteristics, expression systems, and potential applicability as ideal candidates to combat emerging virulent pathogens. Finally, the potential of VLP-based vaccine as viable and efficient immunizing agents to induce immunity against virulent infectious agents, including, SARS-CoV-2 and protein nanoparticle-based vaccines has been elaborated. Thus, VLP vaccines may serve as an effective alternative to conventional vaccine strategies in combating emerging infectious diseases.

show abstract

Section: Expression Host Systems For Virus-like Particle Productionmentioning

confidence: 99%

Virus-Like Particles: Revolutionary Platforms for Developing Vaccines Against Emerging Infectious Diseases

et al. 2022

View full text Add to dashboard Cite

show abstract

“…While most studies were performed using baculovirus-based expression, other recombinant systems such as plants [101], yeast [106,107] and possibly even bacteria [108] can also be used.…”

Section: L2 Epitopes Displayed On Papillomavirus L1 Vlpmentioning

confidence: 99%

Progress in L2-Based Prophylactic Vaccine Development for Protection against Diverse Human Papillomavirus Genotypes and Associated Diseases

Olczak¹,

Roden²

2020

Vaccines

View full text Add to dashboard Cite

The human papillomaviruses (HPVs) are a family of small DNA tumor viruses including over 200 genotypes classified by phylogeny into several genera. Different genera of HPVs cause ano-genital and oropharyngeal cancers, skin cancers, as well as benign diseases including skin and genital warts. Licensed vaccines composed of L1 virus-like particles (VLPs) confer protection generally restricted to the ≤9 HPV types targeted. Here, we examine approaches aimed at broadening the protection against diverse HPV types by targeting conserved epitopes of the minor capsid protein, L2. Compared to L1 VLP, L2 is less immunogenic. However, with appropriate presentation to the immune system, L2 can elicit durable, broadly cross-neutralizing antibody responses and protection against skin and genital challenge with diverse HPV types. Such approaches to enhance the strength and breadth of the humoral response include the display of L2 peptides on VLPs or viral capsids, bacteria, thioredoxin and other platforms for multimerization. Neither L2 nor L1 vaccinations elicit a therapeutic response. However, fusion of L2 with early viral antigens has the potential to elicit both prophylactic and therapeutic immunity. This review of cross-protective HPV vaccines based on L2 is timely as several candidates have recently entered early-phase clinical trials.

show abstract

“…A study has also shown that in the case of women lacking L. crispatus, the competitive proliferation of three bacterial groups, L. iners, Gardnerella vaginalis, and Anaerococcus vaginalis, leads to the development of SIL [19]. Some studies have shown that Lactobacillus has a plasmid-like function, which can integrate HPV16 gene, thereby preventing the virus from integrating with host cells [20]. The loss of the dominant position of Lactobacillus will promote the colonization of anaerobic bacterial species and increase the diversity of microorganisms.…”

Section: Introductionmentioning

confidence: 99%

Correlations between microbiota-derived metabolites and cervical precancerous lesions in women with HPV

Shen¹,

Zhao²,

Shan

et al. 2023

Preprint

View full text Add to dashboard Cite

High-risk human papillomavirus (HR-HPV) causes cervical squamous intraepithelial lesions and cervical cancer; however, only a small group of people infected with HR-HPV will develop cervical precancerous lesions or cervical cancer. Current studies have shown that an imbalance in the cervicovaginal flora may be one of the factors for persistent HR-HPV infection. Cervicovaginal secretions are easily accessible and may be advantageous tools for diagnosing risks for cervical cancer. Thus, in this pilot study we collected 156 cervicovaginal secretions of women with HPV infection with precancerous cervical lesions to determine whether microflora-derived metabolites present in the secretion can be used for assessing the risk of cervical cancer in patients. We performed 16S rRNA sequencing and metabolomic analyses to identify changes in the cervicovaginal flora and its metabolites in patients with HPV infection with different grades of cervical lesions. We detected 164 common known metabolites in the three groups of samples. There are significant differences in the metabolic patterns of cervical lesion groups with different degrees, and multiple metabolites are significantly related to the vaginal flora. Among them, the content of metabolites such as taurine, guanine, and uric acid are significantly different in patients with persistent HR-HPV infection with different degrees of cervical lesions. Taurine is positively correlated with Weissella, and negatively correlated with Corynebacterium. Related. Which may involve 7 related metabolic pathways. Metabolites such as taurine, guanine, and uric acid are closely related to the activation of the human immune system. Cervical vaginal flora can regulate the synthesis and decomposition of amino acids, purines, and uric acid, and may play a major role in activating inflammation and the immune system. These metabolisms It is worthy of further research to assess the risk of HR-HPV infection progressing to cervical cancer.

show abstract

VLP Production from Recombinant L1/L2 HPV-16 Protein Expressed in Pichia Pastoris

Abstract: The present study will pave the way for producing recombinant pan-HPV vaccine.

Cited by 9 publications

References 0 publications

Virus-Like Particles: Revolutionary Platforms for Developing Vaccines Against Emerging Infectious Diseases

Virus-Like Particles: Revolutionary Platforms for Developing Vaccines Against Emerging Infectious Diseases

Progress in L2-Based Prophylactic Vaccine Development for Protection against Diverse Human Papillomavirus Genotypes and Associated Diseases

Correlations between microbiota-derived metabolites and cervical precancerous lesions in women with HPV

Contact Info

Product

Resources

About